WO2017154270A1 - 成分測定装置、成分測定方法及び成分測定プログラム - Google Patents
成分測定装置、成分測定方法及び成分測定プログラム Download PDFInfo
- Publication number
- WO2017154270A1 WO2017154270A1 PCT/JP2016/084049 JP2016084049W WO2017154270A1 WO 2017154270 A1 WO2017154270 A1 WO 2017154270A1 JP 2016084049 W JP2016084049 W JP 2016084049W WO 2017154270 A1 WO2017154270 A1 WO 2017154270A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wavelength
- component
- absorbance
- measurement
- value
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
- G01N2021/3148—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths using three or more wavelengths
Definitions
- the present invention relates to a component measuring device, a component measuring method, and a component measuring program, and more particularly, to a component measuring device, a component measuring method, and a component measuring program for measuring a component to be measured in blood.
- the blood includes a portion containing the component to be measured
- a method is known in which the amount and concentration of a component to be measured are measured by separating the component into components that do not contain the component to be measured.
- the glucose concentration mg / dL
- whole blood measurement using absorptiometry is known as a technique for measuring a component to be measured in blood without separating the component to be measured from blood and without further lysing the blood. ing.
- the time required for measuring the component to be measured can be shortened as compared with the above-described method of performing the measurement component separation step and the hemolysis step.
- the other components may cause optical phenomena such as light absorption and light scattering, and as a result, may act as a disturbance factor in measurement. . Therefore, in order to maintain the measurement accuracy of the component to be measured, it is necessary to remove the influence of the disturbance factor, and various methods for removing the influence of the disturbance factor have been proposed.
- the influence amount of the disturbance factor at the measurement wavelength is estimated from the actual measurement value in the long wavelength region longer than the measurement wavelength, and the actual measurement value at the measurement wavelength is used as the influence amount of the estimated disturbance factor.
- a component measuring apparatus and a component measuring method for measuring a glucose concentration in a plasma component by further correcting an actual measurement value at a measurement wavelength using a predicted hematocrit value after the correction is performed.
- the glucose concentration in the plasma component is measured with high accuracy from the blood without separating the plasma component containing glucose as the component to be measured from the blood. can do.
- there is room for further improvement in the accuracy of estimating the influence amount of disturbance factors such as light scattering by blood cell components in blood and light absorption by hemoglobin in blood.
- An object of the present invention is to provide a component measuring apparatus, a component measuring method, and a component measuring program capable of measuring a predetermined measured component with high accuracy without separating the predetermined measured component from blood. To do.
- the component measuring apparatus is a component to be measured in blood based on the optical characteristics of a mixture containing a dye component colored by a color reaction between the component to be measured in blood and a reagent.
- a component measuring apparatus that measures the absorbance of the mixture at the measurement wavelength based on the information of scattered light and the ratio of reduced hemoglobin to oxidized hemoglobin in red blood cells.
- the actual measurement value is the fifth actual measurement value
- the measurement belonging to the wavelength range corresponding to the full width at half maximum of the peak wavelength region in the absorbance spectrum of the dye component More than the measurement wavelength belonging to the wavelength range corresponding to the full width at half maximum
- the first actual measurement value and the second actual measurement value which are the absorbances of the mixture at the first wavelength and the second wavelength belonging to a longer wavelength range than the wavelength, respectively.
- the third actual measurement value and the fourth actual measurement value which are the absorbances of the mixture at the third wavelength and the fourth wavelength belonging to the short wavelength region, respectively
- the fifth actual measurement value which is the absorbance of the mixture at the measurement wavelength
- an absorbance correction unit that corrects the fifth actual measurement value using the first actual measurement value to the fourth actual measurement value, and uses the reduced hemoglobin as the third wavelength.
- the component measuring apparatus uses, as the third wavelength, a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is a predetermined threshold or more, and the fourth wavelength. It is preferable to use a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is less than the predetermined threshold.
- the component measuring apparatus as one embodiment of the present invention, it is preferable to use a wavelength where the absorption coefficient of reduced hemoglobin and the absorption coefficient of oxyhemoglobin are equal as the third wavelength. That is, it is preferable to use a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is 1.
- the third wavelength belongs to a range of 520 nm to 550 nm or a range of 565 nm to 585 nm.
- the fourth wavelength belongs to a range greater than 550 nm and less than 565 nm, or greater than 585 nm and less than 600 nm.
- the difference in absorption coefficient between reduced hemoglobin and oxyhemoglobin is the second wavelength as the first wavelength. It is preferable to use a wavelength that is equal to or less than a predetermined value and use a wavelength that is greater than the second predetermined value as the second wavelength.
- the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin as the first wavelength is the first wavelength.
- a wavelength that is not less than one threshold and not more than a second threshold, and the second wavelength is a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is less than the first threshold, or It is preferable to use a wavelength that is greater than the second threshold.
- the component measuring apparatus it is preferable to use a wavelength having the same absorption coefficient as that of reduced hemoglobin and that of oxyhemoglobin as the first wavelength.
- the first wavelength preferably belongs to a range of 790 nm to 810 nm.
- the second wavelength preferably belongs to a wavelength at which the absorbance of the dye component is 10% or less of the absorbance of the dye component at the measurement wavelength.
- the second wavelength is preferably such that the absorbance of the dye component is 0% of the absorbance of the dye component at the measurement wavelength.
- the measurement wavelength preferably belongs to a range of 600 nm or more and 700 nm or less.
- the component measuring method includes a component to be measured in blood based on the optical characteristics of a mixture containing a pigment component colored by a color reaction between the component to be measured in blood and a reagent. Is a component measurement method that measures the absorbance of the mixture at the measurement wavelength based on the scattered light information and the ratio of reduced hemoglobin to oxidized hemoglobin in red blood cells.
- the component measurement program according to the third aspect of the present invention is based on the optical characteristics of a mixture containing a dye component colored by a color reaction between a component to be measured and a reagent in blood.
- a component measuring apparatus capable of measuring a predetermined measured component with high accuracy without separating the predetermined measured component from blood. it can.
- FIG. 1 It is a top view of the component measuring device set by which the component measuring chip was mounted
- FIG. 12A is a graph showing an error between the absorbance and the true value measured by the component measuring method as one embodiment of the present invention
- FIG. 12B is a graph showing the component measuring method as a comparative example. It is a graph which shows the error of the light absorbency measured and a true value.
- FIG. 16A is a graph showing an error between the absorbance and the true value measured by the component measurement method as one embodiment of the present invention
- FIG. 16B is a graph showing the component measurement method as a comparative example. It is a graph which shows the error of the light absorbency measured and a true value.
- FIG. 1 is a top view showing a component measuring device set 100 in which the component measuring chip 2 is mounted on the component measuring device 1 in the present embodiment.
- FIG. 2 is an enlarged cross-sectional view of the vicinity of a portion where the component measuring chip 2 is mounted in the cross section taken along the line II of FIG.
- the component measuring device set 100 includes a component measuring device 1 and a component measuring chip 2.
- the component measuring apparatus 1 of this embodiment is a blood glucose level measuring apparatus capable of measuring the concentration (mg / dL) of glucose in a plasma component as a component to be measured in blood.
- the component measurement chip 2 of the present embodiment is a blood glucose measurement chip that can be attached to the tip of a blood glucose measurement device as the component measurement device 1.
- blood as used herein means whole blood that is not separated for each component but includes all components.
- the component measuring apparatus 1 includes a housing 10 made of a resin material, a button group provided on the upper surface of the housing 10, a liquid crystal or an LED (abbreviation of Light Emitting Diode) provided on the upper surface of the housing 10, and the like.
- a display unit 11 and a removal lever 12 that is operated when removing the component measurement chip 2 attached to the component measurement device 1 are provided.
- the button group of the present embodiment includes a power button 13 and an operation button 14.
- the housing 10 is provided with the above-described button group and the display unit 11 on the upper surface (see FIG. 1).
- the main body 10a has a substantially rectangular outer shape when viewed from above, and protrudes outward from the main body 10a. (See FIG. 1) and a chip mounting portion 10b provided with a removal lever 12. As shown in FIG. 2, inside the chip mounting portion 10b, a chip mounting space S having a tip opening formed at the tip surface of the chip mounting portion 10b as one end is partitioned.
- the component measuring chip 2 When the component measuring chip 2 is mounted on the component measuring apparatus 1, the component measuring chip 2 is inserted into the chip mounting space S from the outside through the tip opening, and the component measuring chip 2 is pushed into a predetermined position to The chip mounting portion 10b of the measuring device 1 is in a state where the component measuring chip 2 is locked, and the component measuring chip 2 can be mounted on the component measuring device 1.
- the locking of the component measuring chip 2 by the component measuring apparatus 1 can be realized by various configurations, for example, by providing a claw portion that can be engaged with a part of the component measuring chip 2 in the chip mounting portion 10b.
- the chip mounting portion of the component measuring apparatus 1 is operated by operating the above-described removal lever 12 from the outside of the housing 10.
- the locking state of the component measuring chip 2 by 10b is released, and the eject pin 26 (see FIG. 2) in the housing 10 moves in conjunction with the component measuring chip 2 so that the component measuring chip 2 can be detached from the component measuring apparatus 1.
- the housing 10 of the present embodiment is configured to include a substantially rectangular main body portion 10a and a chip mounting portion 10b protruding outward from the main body portion 10a in a top view (see FIG. 1).
- the shape of the housing 10 of the present embodiment is not limited. Therefore, in addition to the shape of the housing 10 of the present embodiment, various shapes that are easy for the user to hold with one hand can be employed.
- the display unit 11 displays information on the component to be measured measured by the component measuring apparatus 1.
- the glucose concentration (mg / dL) measured by the blood sugar level measuring device as the component measuring device 1 can be displayed on the display unit 11.
- the display unit 11 may display not only information on the component to be measured but also various information such as measurement conditions of the component measuring apparatus 1 and instruction information for instructing a user to perform a predetermined operation. The user can operate the power button 13 and the operation button 14 of the button group while confirming the content displayed on the display unit 11.
- FIG. 3 is a top view showing the component measuring chip 2.
- 4 is a cross-sectional view taken along the line II-II in FIG.
- the component measuring chip 2 includes a base member 21 having a substantially rectangular plate shape, a coloring reagent 22 as a reagent held by the base member 21, and the base member 21. And a cover member 25 for covering.
- a groove is formed on the outer surface of the base member 21 on one side in the thickness direction.
- the groove of the base member 21 is covered with the cover member 25 to become a hollow portion extending in a direction orthogonal to the thickness direction, and this hollow portion constitutes the flow path 23 of the component measuring chip 2.
- a supply unit 24 capable of supplying blood from the outside is formed.
- a coloring reagent 22 is held at the groove bottom of the groove of the base member 21 in the inner wall of the flow path 23, and blood supplied from the outside to the supply unit 24 flows using, for example, capillary action.
- the flow path 23 of this embodiment is comprised by the hollow part divided by the base member 21 and the cover member 25, a flow path is not restricted to this structure. You may form a flow path only by the groove
- a transparent material for light transmission As the material of the base member 21 and the cover member 25, it is preferable to use a transparent material for light transmission.
- transparent organic resin materials such as polyethylene terephthalate (PET), polymethyl methacrylate (PMMA), polystyrene (PS), cyclic polyolefin (COP), cyclic olefin copolymer (COC), and polycarbonate (PC); glass, quartz, etc.
- PET polyethylene terephthalate
- PMMA polymethyl methacrylate
- PS polystyrene
- COP cyclic polyolefin
- COC cyclic olefin copolymer
- PC polycarbonate
- the coloring reagent 22 as a reagent reacts with a component to be measured in blood to cause a color reaction that develops a color corresponding to the blood concentration of the component to be measured.
- the coloring reagent 22 of the present embodiment is applied to the groove bottom of the groove as the flow path 23.
- the coloring reagent 22 of this embodiment reacts with glucose as a component to be measured in blood.
- Examples of the coloring reagent 22 of the present embodiment include (i) glucose oxidase (GOD), (ii) peroxidase (POD), and (iii) 1- (4-sulfophenyl) -2,3-dimethyl-4-amino.
- examples thereof include a mixed reagent of (GDH), a tetrazolium salt, and an electron mediator.
- a buffering agent such as a phosphate buffer may be included.
- the types and components of the coloring reagent 22 are not limited to these.
- the peak wavelength in the absorbance spectrum of the pigment component colored by the color reaction between glucose in the blood and the coloring reagent 22 is attributed to the light absorption characteristics of hemoglobin in blood cells. A wavelength different from the peak wavelength is used.
- the absorbance spectrum of the dye component that is colored by the color reaction between glucose in the blood and the coloring reagent 22 has a peak wavelength near 650 nm, but the peak wavelength is around 650 nm. It is not limited to what becomes. Details of this will be described later.
- the component measuring chip 2 is mounted in the chip mounting portion 10b. Then, when blood is supplied to the supply unit 24 provided at one end of the component measuring chip 2, the blood moves in the flow path 23 by, for example, capillary action, and the color reagent 22 in the flow path 23 is held. It reaches the position and reacts with the coloring reagent 22 at this holding position.
- the so-called colorimetric component measuring apparatus 1 irradiates light toward the holding position of the coloring reagent 22, detects the amount of transmitted light (or the amount of reflected light), and correlates with the intensity of coloring according to the blood concentration. A detection signal is obtained. And the component measuring apparatus 1 can measure a to-be-measured component by referring the calibration curve created beforehand. In addition, the component measuring apparatus 1 of this embodiment measures the glucose concentration (mg / dL) in the plasma component in blood.
- FIG. 5 is an electrical block diagram of the component measuring apparatus 1 shown in FIGS. 1 and 2.
- FIG. 5 also shows a cross section (same cross section as FIG. 4) of the component measuring chip 2 mounted on the component measuring apparatus 1.
- FIG. 5 what expanded the vicinity of the component measurement chip
- tip 2 is shown separately on the upper left.
- the component measuring apparatus 1 includes a calculation unit 60, a memory 62, a power supply circuit 63, in addition to the housing 10, the display unit 11, the removal lever 12, the power button 13 and the operation button 14 described above. And a measurement optical system 64.
- the calculation unit 60 is configured by an MPU (Micro-Processing Unit) or a CPU (Central Processing Unit), and can read out and execute a program stored in the memory 62 or the like, thereby realizing control operations of the respective units.
- the memory 62 is configured by a non-transitory storage medium that is volatile or nonvolatile, and can read or write various data (including a program) necessary for executing the component measurement method shown here.
- the power supply circuit 63 supplies power to each unit in the component measuring apparatus 1 including the calculation unit 60 or stops supplying the power according to the operation of the power button 13.
- the measurement optical system 64 is an optical system capable of acquiring the optical characteristics of the mixture X containing a color component colored by the color reaction between the blood and the coloring reagent 22 as a reagent.
- the measurement optical system 64 includes a light emitting unit 66, a light emission control circuit 70, a light receiving unit 72, and a light reception control circuit 74.
- the light emitting unit 66 of this embodiment includes five types of light sources 67a, 67b, 67c, 67d and 68.
- the light sources 67a to 67d and 68 emit light (eg, visible light, infrared light) having different spectral radiation characteristics.
- the light source 67a is “first light source 67a”
- the light source 67b is “second light source 67b”
- the light source 67c is “third light source 67c”
- the light source 67d is “fourth light source 67d”
- the light source 68 is “ 5th light source 68 ".
- the emission wavelengths of the first to fifth light sources 67a, 67b, 67c, 67d and 68 include the first to fifth wavelengths ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4 and ⁇ 5, and are light sources having different emission wavelengths.
- various light emitting elements including LED elements, organic EL (Electro-Luminescence) elements, inorganic EL elements, and LD (Laser Diode) elements can be applied. .
- the light receiving unit 72 of the present embodiment is composed of a single light receiving element disposed facing the light emitting unit 66 and the component measuring chip 2 therebetween.
- the light receiving unit 72 receives the transmitted light that is irradiated from the first to fifth light sources 67a to 67d and 68 of the light emitting unit 66 to the holding position of the color reagent 22 of the component measuring chip 2 and transmitted through the component measuring chip 2.
- various photoelectric conversion elements including a PD (abbreviation of Photo Diode) element, a photoconductor (photoconductor), and a phototransistor (abbreviation of Photo Transistor) can be applied.
- the light emission control circuit 70 turns on or turns off the first to fifth light sources 67a to 67d and 68 by supplying driving power signals to the first to fifth light sources 67a to 67d and 68, respectively.
- the light reception control circuit 74 obtains a digital signal (hereinafter referred to as a detection signal) by performing logarithmic conversion and A / D conversion on the analog signal output from the light receiving unit 72.
- FIG. 6 is a functional block diagram of the calculation unit 60 shown in FIG.
- the calculation unit 60 realizes the functions of a measurement instruction unit 76 that instructs a measurement operation by the measurement optical system 64 and a concentration measurement unit 77 that measures the concentration of the component to be measured using various data.
- the concentration measurement unit 77 includes an absorbance acquisition unit 78 and an absorbance correction unit 84.
- the memory 62 stores measured data 85 of the first measured value D1 to the fifth measured value D5, which are the absorbances of the mixture X at the first wavelength ⁇ 1 to the fifth wavelength ⁇ 5 measured by the measurement optical system 64, respectively.
- Correction coefficient data 86 including a group of correction coefficients correlated with the absorbance of the mixture X at each of the first wavelength ⁇ 1 to the fourth wavelength ⁇ 4, and the absorbance of the mixture X actually measured at the fifth wavelength ⁇ 5.
- Calibration curve showing the relationship between the absorbance of the pigment component in the mixture X obtained by correction by the above and various physical quantities (for example, glucose concentration), the calibration curve showing the relationship between the absorbance of the hemoglobin in the mixture X and the hematocrit value, etc.
- Calibration curve data 90 is stored.
- the “hematocrit value” is a percentage of the volume ratio of blood cell components in blood to blood (whole blood).
- the color reaction between glucose as the component to be measured in the blood and the coloring reagent 22 is performed with the blood (whole blood) and the coloring reagent 22 without separating the plasma component containing glucose from the blood.
- One embodiment of the present invention for estimating the absorbance at a predetermined measurement wavelength of a dye component colored by a color reaction between glucose and the coloring reagent 22 based on the absorbance at various wavelengths of the entire mixture X obtained by the color reaction The component measuring method as a form is demonstrated.
- FIG. 7 shows the absorbance spectra of six types of mixtures X obtained by color-reacting each of six types of blood specimens with known hematocrit values and glucose concentrations with the coloring reagent 22. These six blood samples are referred to as first to sixth samples.
- the first sample has a hematocrit value of 20% and a glucose concentration of 0 mg / dL (indicated as “Ht20 bg0” in FIG. 7).
- the second sample has a hematocrit value of 20% and a glucose concentration of 100 mg / dL (indicated as “Ht20 bg100” in FIG. 7).
- the third sample has a hematocrit value of 20% and a glucose concentration of 400 mg / dL (indicated as “Ht20 bg400” in FIG. 7).
- the fourth sample has a hematocrit value of 40% and a glucose concentration of 0 mg / dL (indicated as “Ht40 bg0” in FIG. 7).
- the fifth sample has a hematocrit value of 40% and a glucose concentration of 100 mg / dL (indicated as “Ht40 bg100” in FIG. 7).
- the sixth sample has a hematocrit value of 40% and a glucose concentration of 400 mg / dL (indicated as “Ht40 bg400” in FIG. 7).
- FIG. 8 shows the absorbance spectrum of each of the seven blood samples whose hematocrit value and glucose concentration are known. These seven blood samples are referred to as first to seventh samples.
- the first to sixth samples are the same as the first to sixth samples shown in FIG.
- the seventh sample has a hematocrit value of 70% and a glucose concentration of 100 mg / dL.
- FIG. 8 shows only three curves having different hematocrit values. Specifically, three curves with hematocrit values of 20% (indicated as “Ht20” in FIG. 8), 40% (indicated as “Ht40” in FIG. 8), and 70% (indicated as “Ht70” in FIG. 8). Only shows.
- the measurement result of the dye component may be affected by the occurrence of an optical phenomenon.
- an optical phenomenon For example, “light scattering” due to blood cell components in blood, the surface of the component measuring chip, or fine particles such as dust adhering to the component measuring chip, or a pigment component different from the pigment component to be measured (specifically, hemoglobin ) Occurs, an absorbance greater than the true value tends to be measured.
- the absorbance spectrum of the blood sample shown in FIG. 8 has two peaks centered around 540 nm and 570 nm. These two peaks are mainly due to light absorption of oxyhemoglobin in erythrocytes. Further, in the absorbance spectrum of the blood sample shown in FIG. 8, in the wavelength region of 600 nm or more, the absorbance gradually decreases substantially linearly as the wavelength becomes longer. This substantially linear portion is mainly caused by light scattering of fine particles such as dust and dust adhering to the blood cell component and the component measuring chip.
- the influence of light scattering by blood cell components or the like is dominant in the absorbance of the blood sample in the wavelength region longer than 600 nm.
- the absorbance of the blood sample in the wavelength region shorter than 600 nm is more influenced by light absorption by hemoglobin than by light scattering by blood cell components and the like.
- the absorbance spectrum of the mixture X shown in FIG. 7 has a trend curve in which the absorbance gradually decreases as the wavelength increases, similar to the absorbance spectrum of blood shown in FIG.
- the absorbance spectrum of the mixture X shown in FIG. 7 has an increased absorbance over the visible light wavelength region of 600 nm to 700 nm, as compared with the curve shown in FIG.
- the absorbance increasing from about 600 nm to 700 nm is mainly due to the absorption characteristics of the dye component that develops color by the color reaction between glucose in the blood and the coloring reagent 22.
- a predetermined measurement wavelength For example, it is necessary to remove influences (noise) such as light scattering due to blood cell components and light absorption due to hemoglobin from an actual measurement value of absorbance at 650 nm.
- the influence (noise) of light scattering due to blood cell components, etc., or light absorption due to hemoglobin at a predetermined measurement wavelength (for example, 650 nm) where the light absorption rate of the dye component to be measured is high is estimated. It is necessary to correct the measured value of the absorbance at the measurement wavelength.
- the component measuring apparatus 1 measures a component to be measured in blood based on the optical characteristics of the mixture X containing a dye component colored by a color reaction between blood and a coloring reagent 22 as a reagent. Specifically, in this embodiment, the concentration of glucose contained in plasma components in blood is measured.
- the component measuring apparatus 1 includes the optical characteristics of the blood cell component in the blood, the surface of the component measuring chip 2, or fine particles such as dust attached to the component measuring chip 2, and the ratio between the reduced hemoglobin and the oxidized hemoglobin in the red blood cells.
- the glucose concentration in the blood is calculated by correcting the measured value of the absorbance of the mixture X at the measurement wavelength.
- the component measuring method by the component measuring apparatus 1 includes information on scattered light by blood cell components in blood, the surface of the component measuring chip 2 or fine particles such as dust attached to the component measuring chip 2, and reduction in red blood cells.
- the method includes a step of correcting the actual measurement value of the absorbance of the mixture X at the measurement wavelength based on the ratio of hemoglobin and oxygenated hemoglobin.
- FIG. 9 shows the absorption coefficient of reduced hemoglobin (indicated as “Hb” in FIG. 9) and the absorption coefficient of oxidized hemoglobin (indicated as “HbO 2 ” in FIG. 9).
- Hemoglobin in erythrocytes mainly contains oxygenated hemoglobin combined with oxygen and reduced hemoglobin in which oxygen is dissociated at a place where the oxygen partial pressure is low.
- Oxyhemoglobin plays a role in which reduced hemoglobin passes through the lungs and binds to oxygen and transports oxygen through the artery and into the body, and can be confirmed in the arterial blood. For example, when blood is collected from the abdomen of a finger, the amount of oxyhemoglobin is relatively large because it becomes capillary blood. Conversely, reduced hemoglobin can be confirmed in a large amount in venous blood.
- the absorbance obtained at the measurement wavelength corresponding to the dye component to be measured can be corrected using, for example, the hematocrit value without considering the ratio of reduced hemoglobin and oxidized hemoglobin. It is common. However, as shown in FIG. 9, the absorption coefficient of reduced hemoglobin and the absorption coefficient of oxyhemoglobin do not match, and the absorption amount by reduced hemoglobin and the absorption amount by oxyhemoglobin differ depending on the wavelength.
- FIG. 10 shows the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin.
- the absorption coefficient of reduced hemoglobin is about 0.9 and the absorption coefficient of oxyhemoglobin is about 0.09. That is, the absorption coefficient of oxyhemoglobin corresponds to about 10% of the absorption coefficient of total hemoglobin.
- the measurement wavelength for measuring the absorbance of the pigment component contained in the mixture X is set to 650 nm, and light scattering of blood cell components and the like from the measured value of the absorbance of the mixture X measured at this measurement wavelength. And correction to remove the influence of light absorption of hemoglobin in consideration of the ratio of reduced hemoglobin and oxidized hemoglobin. Thereby, the light absorbency of the pigment
- the coloring reagent 22 used in the present embodiment a coloring component having a peak of absorbance around 600 nm is used, which is colored by a color reaction with glucose in blood.
- the measurement wavelength for measuring the absorbance of the components is 650 nm.
- the measurement wavelength for measuring the absorbance of the dye component to be measured is a wavelength at which the light absorption rate of the dye component is relatively large and a wavelength that is relatively less affected by the light absorption of hemoglobin is used. Good.
- the wavelength range W3 (corresponding to the full width at half maximum of the peak wavelength range in the absorbance spectrum of the dye component to be measured) and having a relatively small ratio of absorbance due to light absorption of hemoglobin to the total absorbance (FIG. 7, The wavelength may belong to (see FIG. 8).
- the wavelength range corresponding to the full width at half maximum of the peak wavelength range is the half value at the long wavelength side from the wavelength indicating the half value at the short wavelength side when the full width at half maximum of the peak wavelength range in the absorbance spectrum is specified.
- the peak wavelength is around 600 nm, and the wavelength range corresponding to the full width at half maximum is about 500 nm to about 700 nm. Further, the influence of light absorption of hemoglobin on the total absorbance is relatively small in the wavelength region of 600 nm or more. Therefore, in this embodiment, the wavelength range W3 corresponding to the full width at half maximum of the peak wavelength range in the absorbance spectrum of the dye component to be measured, and the ratio of absorbance due to light absorption of hemoglobin to the total absorbance is relatively small, It is 600 nm or more and 700 nm or less.
- the measurement wavelength is not limited to 650 nm of the present embodiment, and another wavelength belonging to the range of 600 nm to 700 nm may be used as the measurement wavelength.
- the signal representing the absorbance of the dye component is strong and the ratio of the absorbance due to light absorption of hemoglobin relative to the total absorbance is in a very small wavelength range, the absorbance derived from the dye component can be measured more accurately. It is preferable to set the measurement wavelength near 650 nm, which is slightly longer than the wavelength near 600 nm, which is the peak wavelength in the absorbance spectrum.
- the measurement wavelength is preferably a wavelength belonging to a range of 630 nm to 680 nm, more preferably a wavelength belonging to a range of 640 nm to 670 nm, and particularly preferably 650 nm as in the present embodiment.
- a dye component is preferably a tetrazolium salt, and most preferably, for example, WST-4.
- the coloring reagent 22 is used such that the full width at half maximum of the peak wavelength range in the absorbance spectrum of the dye component is about 500 nm to about 700 nm.
- the full width at half maximum of the peak wavelength range is within this range.
- Coloring reagents different from those described above may be used. However, as described above, in consideration of the absorption characteristics of hemoglobin, it is desirable that the wavelength region (600 nm or less) in which the absorbance due to light absorption of hemoglobin increases does not overlap with the measurement wavelength in the absorbance spectrum of the dye component.
- the component measuring apparatus 1 measures the absorbances of the mixture X at four first wavelengths ⁇ 1 to ⁇ 4 that are different from the measurement wavelength (650 nm), and the four first measured values D1 to fourth measured values D4.
- the fifth actual measurement value D5 of the absorbance of the mixture X at the measurement wavelength is corrected using the predetermined correction coefficient data 86, and the absorbance of the dye component at the measurement wavelength is estimated.
- the measurement wavelength is referred to as “fifth wavelength ⁇ 5”.
- the component measuring apparatus 1 uses the first measured value D1 to the fourth measured value D4 described above as two first wavelengths ⁇ 1 and second wavelength longer than the fifth wavelength ⁇ 5 that is the measured wavelength.
- the four first measured values D1 to fourth measured values D4 described above are affected by light scattering of blood cell components or the like in the total absorbance on the longer wavelength side than the fifth wavelength ⁇ 5 that is the measurement wavelength.
- the fifth wavelength ⁇ 5 which is the measurement wavelength
- the component measuring apparatus 1 uses the wavelength range corresponding to the full width at half maximum of the peak wavelength range in the absorbance spectrum of the dye component as the measurement target as the first actual measurement value D1 and the second actual measurement value D2 described above (this embodiment).
- the component measuring apparatus 1 uses the wavelength range (500 to 700 nm) corresponding to the full width at half maximum of the peak wavelength range in the absorbance spectrum of the dye component to be measured as the above-described third actual measurement value D3 and fourth actual measurement value D4.
- a third actually measured value that is the absorbance of the mixture X in each of the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 belonging to the short wavelength region W2 belonging to the shorter wavelength region than the wavelength range W3, for example, the shorter wavelength region W2 than the wavelength range W3 D3 and the fourth measured value D4 are used.
- the absorbance acquisition unit 78 of the component measuring apparatus 1 acquires the first measured value D1 to the fifth measured value D5 described above. Specifically, the first to fifth light sources 67a to 67d and 68 of the light emitting unit 66 are irradiated with irradiation light including emission wavelengths of the first wavelength ⁇ 1 to the fifth wavelength ⁇ 5. And the light-receiving part 72 receives the transmitted light which permeate
- the value data 85 is stored in the memory 62.
- the absorbance acquisition unit 78 of the component measuring apparatus 1 can acquire the actual measurement data 85 from the memory 62.
- the means by which the absorbance acquisition unit 78 acquires the first actual measurement value D1 to the fifth actual measurement value D5 is not limited to the above-described means, and can be acquired by various known means.
- the absorbance correction unit 84 of the component measuring apparatus 1 corrects the fifth actual measurement value D5 using the first actual measurement value D1 to the fourth actual measurement value D4, and the fifth wavelength ⁇ 5 (650 nm in this example) which is the measurement wavelength.
- the absorbance of the dye component at is estimated.
- the absorbance spectrum of the mixture X is substantially linear, and thus the absorbance at the first wavelength ⁇ 1. If the first actual measurement value D1 and the second actual measurement value D2 that is the absorbance at the second wavelength ⁇ 2 can be acquired, the slope between the first actual measurement value D1 and the second actual measurement value D2 is obtained, and the measured wavelength is obtained. It is possible to estimate to some extent noise other than the absorbance of the dye component at a certain fifth wavelength ⁇ 5.
- the component measuring apparatus 1 derives the glucose concentration in the blood in consideration of the ratio of the reduced hemoglobin and the oxidized hemoglobin in the red blood cells in addition to the optical characteristics due to blood cell components in the blood. Therefore, the component measuring apparatus 1 can perform more accurate correction by using two wavelengths (third wavelength and fourth wavelength) selected based on the ratio of reduced hemoglobin and oxyhemoglobin.
- a wavelength at which the difference in absorption coefficient between reduced hemoglobin and oxidized hemoglobin is equal to or less than the first predetermined value is used as the third wavelength ⁇ 3, and a reduced wavelength between reduced hemoglobin and oxidized hemoglobin is used as the fourth wavelength ⁇ 4.
- a wavelength at which the difference in absorption coefficient is larger than the first predetermined value is used. More specifically, as the third wavelength ⁇ 3, a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin (see FIG. 10) is equal to or greater than the first threshold as a predetermined threshold is used.
- a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is less than the first threshold value described above is used.
- the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 two wavelengths, a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is not less than the first threshold and a wavelength that is less than the first threshold, Use.
- the two wavelengths selected based on the ratio between reduced hemoglobin and oxidized hemoglobin are preferably two wavelengths that have a large difference in light absorption of hemoglobin depending on the ratio between reduced hemoglobin and oxidized hemoglobin. Therefore, in the present embodiment, as the third wavelength ⁇ 3, a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is 0.8 or more, that is, a wavelength belonging to the range of 520 nm to 550 nm, or 565 nm to A wavelength belonging to the range of 585 nm is used.
- the wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is less than 0.8, that is, the wavelength that is greater than 550 nm and less than 565 nm, or from 585 nm It is preferable to use a wavelength that is large and belongs to a range of less than 600 nm.
- the third wavelength ⁇ 3 a wavelength at which the absorption coefficient of reduced hemoglobin and the absorption coefficient of oxyhemoglobin are equal, that is, in the present embodiment, so that the total amount of hemoglobin and the hematocrit value can be estimated simultaneously.
- wavelengths near 530 nm, 545 nm, 570 nm, or 580 nm it is particularly preferable to use a wavelength selected from a range of 540 to 545 nm where the absorption coefficient of the entire hemoglobin is large.
- the difference in the absorption coefficient is also in the vicinity of 560 nm where the difference in the absorption coefficient is the largest even in the range larger than 550 nm and less than 565 nm, or in the range larger than 585 nm and less than 600 nm. It is more preferable to set it to around 590 nm at which the value becomes the largest.
- the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 are used in which the difference in the light absorption of the entire hemoglobin becomes large in the short wavelength region W2 in which the light absorption of the entire hemoglobin varies greatly depending on the ratio of the reduced hemoglobin and the oxidized hemoglobin. Accordingly, noise other than the absorbance of the dye component at the fifth wavelength ⁇ 5 (650 nm in the present embodiment), which is the measurement wavelength, can be accurately estimated in consideration of the ratio of reduced hemoglobin and oxidized hemoglobin. Therefore, according to the component measuring apparatus 1, it is possible to accurately measure the absorbance of the dye component at the fifth wavelength ⁇ 5, which is the measurement wavelength, and further measure the component to be measured (glucose concentration measurement in the present embodiment).
- the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 are wavelengths that greatly consider the influence of the ratio of reduced hemoglobin to oxyhemoglobin, but in addition to the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4, It is more preferable to use the same wavelength for the first wavelength ⁇ 1 and the second wavelength ⁇ 2.
- a wavelength at which the difference in absorption coefficient between reduced hemoglobin and oxyhemoglobin is equal to or less than a second predetermined value is used as the first wavelength ⁇ 1 in the long wavelength region W1 where light scattering such as blood cell components is dominant.
- a wavelength that is larger than the second predetermined value is used as the second wavelength ⁇ 2 in the long wavelength region W1.
- the first wavelength ⁇ 1 a wavelength in which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of deoxyhemoglobin is not less than the first threshold and not more than the second threshold is used.
- the second wavelength ⁇ ⁇ b> 2 in the region W ⁇ b> 1 it is preferable to use a wavelength at which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of reduced hemoglobin is less than the first threshold value or a wavelength that is greater than the second threshold value.
- the second threshold value is another predetermined threshold value that is larger than the first threshold value. That is, as the first wavelength ⁇ 1 and the second wavelength ⁇ 2, it is preferable to use two wavelengths in which the ratio of the absorption coefficient of oxyhemoglobin to the absorption coefficient of deoxyhemoglobin is different.
- the influence of light scattering of blood cell components and the like is dominant, but the influence of light absorption of hemoglobin is included to the same extent as the measurement wavelength of the component to be measured, so the first wavelength ⁇ 1 and the second wavelength As ⁇ 2, it is preferable to use two wavelengths in which the light absorption of hemoglobin changes relatively greatly depending on the ratio of reduced hemoglobin and oxidized hemoglobin.
- the first wavelength ⁇ 1 is particularly preferably selected from the vicinity of a wavelength in which the absorption coefficient of reduced hemoglobin and the absorption coefficient of oxyhemoglobin are equal, in which light absorption of hemoglobin appears relatively large in the long wavelength region W1. Then, it is particularly preferable to use a wavelength selected from the range of 800 to 810 nm.
- the second wavelength ⁇ 2 it is preferable to use a wavelength at which the ratio of the absorption coefficient of oxidized hemoglobin to the absorption coefficient of reduced hemoglobin is less than 0.8, or a wavelength greater than 1.5. .
- the refractive index (scattering characteristics) of the medium (here, blood cells) and the light absorption of hemoglobin also change depending on the wavelength, if a wavelength close to the measurement wavelength is used as the second wavelength ⁇ 2, the measurement wavelength (650 nm in this embodiment) is used. ) Can be estimated more accurately by light scattering of blood cell components and the like and light absorption of hemoglobin. That is, in the present embodiment, it is preferable to use a wavelength shorter than the first wavelength ⁇ 1. More specifically, in the present embodiment, it is preferable to use a wavelength that is greater than 700 nm and that is less than 790 nm as the second wavelength ⁇ 2.
- the second wavelength ⁇ 2 is the long wavelength region W1
- the absorbance of the dye component contained in the total absorbance at the second wavelength ⁇ 2 is preferably 10% or less of the absorbance of the pigment component contained in the total absorbance at the measurement wavelength, preferably Is 6% or less, more preferably 3% or less, and still more preferably 0%.
- the second wavelength ⁇ 2 is a wavelength at which the absorbance of the dye component becomes zero, that is, a long wavelength in the peak wavelength region of the absorbance spectrum of the dye component. It is particularly preferable to use a wavelength that becomes the bottom of the side. Therefore, in this embodiment, it is particularly preferable to set 755 nm to the second wavelength ⁇ 2.
- the “total absorbance” of the “absorbance of the dye component contained in the total absorbance” described above means the absorbance of the entire mixture.
- the “absorbance of the dye component” in the “absorbance of the dye component included in the total absorbance” described above is the absorbance of the reactant generated by the color reaction between the measured component in blood and the dye component in the reagent. That is, it means the absorbance derived from the pigment component in the mixture.
- the component measurement apparatus 1 uses the fifth actual measurement value D5, which is the actual measurement value of the absorbance of the mixture X at the measurement wavelength, as the actual measurement value of the absorbance of the mixture X at each of the first wavelength ⁇ 1 to the fourth wavelength ⁇ 4. Correction can be made using the first measured value D1 to the fourth measured value D4, and the absorbance of the dye component at the measurement wavelength can be estimated.
- D5 is the actual measurement value of the absorbance of the mixture X at the measurement wavelength
- the memory 62 of the component measuring apparatus 1 stores the first measured value D1 to the fifth measured value that are the absorbances of the mixture X at the first wavelength ⁇ 1 to the fifth wavelength ⁇ 5 measured by the measuring optical system 64, respectively.
- Calibration curve data 90 indicating the relationship between the absorbance of the pigment component in the mixture X obtained by correction by the data 86 and various physical quantities is stored.
- the absorbance correction unit 84 derives the absorbance of the dye component at the fifth wavelength ⁇ 5, which is the measurement wavelength, based on the actual measurement data 85 and the correction coefficient data 86 stored in the memory 62.
- correction coefficient data 86 is derived by regression analysis performed in advance using the following equation (1).
- B ( ⁇ ) means noise other than the absorbance of the dye component at the wavelength ⁇ , and regression calculation is performed by the equation shown in the above [Expression 1] using various blood samples, and the coefficients b0, b1, b2, b3 and b4 are derived.
- the first wavelength ⁇ 1 is 810 nm
- the second wavelength ⁇ 2 is 750 nm
- the third wavelength ⁇ 3 is 545 nm
- the fourth wavelength As ⁇ 4, 560 nm is used.
- various blood samples are based on six blood samples with different component compositions, each prepared with a hematocrit value adjusted to a range of 10% to 70%, and absorbance spectrum measurement of the adjusted blood sample is performed. Performed and regression analysis is used to derive the coefficients b0, b1, b2, b3 and b4. The total number of observations made this time is 766 times. Then, based on these derived coefficients b0 to b4, a group of correction coefficients that correlate with the absorbance of the mixture X at each of the first wavelength ⁇ 1 to the fourth wavelength ⁇ 4 is derived.
- the actual absorbance value of the mixture X having a measurement wavelength of 650 nm is corrected from the actual absorbance value of the mixture X at 545 nm, 560 nm, 750 nm, and 810 nm.
- the absorbance of the dye component can be estimated.
- each of the coefficients b0 to b4 obtained by the above regression calculation can be determined as a value unique to the measurement system, and does not differ depending on the hematocrit value. Therefore, the numerical values (actually measured values) of B ( ⁇ 1) to B ( ⁇ 4) used for the regression calculation vary depending on the hematocrit value.
- FIG. 11 shows the influence (measured as “W1” in FIG. 11) of the measured value of the long wavelength region W1 in the absorbance (noise) other than the dye component at the measurement wavelength in the regression calculation described above. It is a graph which shows the influence degree (it describes with "W2" in FIG. 11) by the measured value of wavelength range W2. Note that the “influence degree” mentioned here means a data occupancy rate. As shown in FIG. 11, considering the result of the actual measurement data obtained by the above-described regression calculation, the absorbance (noise) other than the dye component at the measurement wavelength is measured using the first actual measurement value D1 to the fourth actual measurement value D4.
- the first actual measurement value D1 and the second actual measurement value D2 at the first wavelength ⁇ 1 and the second wavelength ⁇ 2 in the long wavelength region W1 are 92% as the hematocrit value increases from 10% to 70%.
- the degree of influence decreases from 90% to 90% (see “W1” in FIG. 11).
- the third actual measurement value D3 and the fourth actual measurement value D4 at the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 in the short wavelength region W2 increase from 8% as the hematocrit value increases from 10% to 70%.
- the degree of influence increases to 10% (see “W2” in FIG. 11).
- the absorbance of the dye component at the measurement wavelength can be estimated more accurately.
- the first actual measurement value D1 to the fourth actual measurement value D4 include absorption of the dye component
- correction calculation is performed on the first actual measurement value D1 to the fourth actual measurement value D4
- the absorbance (noise) other than the dye is obtained. It is necessary to calculate B ( ⁇ ).
- the third wavelength ⁇ 3 has a wavelength in which the absorption coefficient of reduced hemoglobin and the absorption coefficient of oxyhemoglobin are equal in the short wavelength region W2 where the influence of light absorption of hemoglobin is overwhelmingly large (in FIG. 9).
- 530 nm, 545 nm, 570 nm, or 580 nm) the absorption coefficient of reduced hemoglobin from the third measured value D3 or in the long wavelength range W1 that is greatly affected by light scattering of the third measured value D3 and blood cell components, etc. It is possible to derive a hematocrit value using the first measured value D1 using a wavelength (800 nm in FIG.
- the hematocrit value can be derived from a calibration curve between the absorbance of the hemoglobin stored in the memory 62 and the hematocrit value.
- FIG. 12A uses 810 nm as the first wavelength ⁇ 1, 750 nm as the second wavelength ⁇ 2, 545 nm as the third wavelength ⁇ 3, 560 nm as the fourth wavelength ⁇ 4, and 650 nm as the fifth wavelength ⁇ 5 as the measurement wavelength.
- it is a graph showing an error between the absorbance other than the dye component at the measurement wavelength derived by the component measuring method of the component measuring apparatus 1 and the true value of the absorbance other than the dye component at the same measurement wavelength.
- the absorbance of the dye component contained in the total absorbance at the second wavelength ⁇ 2 corresponds to 3% of the absorbance at the measurement wavelength.
- FIG. 12A uses 810 nm as the first wavelength ⁇ 1, 750 nm as the second wavelength ⁇ 2, 545 nm as the third wavelength ⁇ 3, 560 nm as the fourth wavelength ⁇ 4, and 650 nm as the fifth wavelength ⁇ 5 as the measurement wavelength.
- FIG. 12A uses 810 nm as the first wavelength ⁇ 1,
- 12B shows, as a comparative example, a measurement wavelength (650 nm) derived by the same method using only two of 810 nm and 750 nm among the above-described first wavelength ⁇ 1 to fourth wavelength ⁇ 4. Is a graph showing an error between the absorbance other than the dye component and the true value of the absorbance other than the dye component at the same measurement wavelength.
- the error shown in FIG. 12A is twice the standard error is 0.0058, whereas the error shown in FIG. 12B is twice the standard error is 0.0109. It can be seen that the error shown in (a) is smaller than the error shown in FIG. That is, according to the above-described component measurement method executed by the component measurement apparatus 1 of the present embodiment, the pigment component at the measurement wavelength estimated from only the two wavelengths in the long wavelength region W1 (810 nm and 750 nm in this verification experiment). It is possible to estimate the absorbance with higher accuracy than the absorbance. In the present example, when the hematocrit is 40%, the absorbance error 0.001 corresponds to an error of 1 [mg / dL] in blood glucose level.
- the component measuring apparatus 1 using this component measuring method can reduce blood sugar level measurement errors for blood having a wide range of hematocrit values of hematocrit of 10% to 70%.
- FIG. 13 is a flowchart showing a component measurement method executed by the component measurement apparatus 1.
- This component measurement method is based on the first measured value D1 that is the absorbance of the mixture X at the first wavelength ⁇ 1, the second measured value D2 that is the absorbance of the mixture X at the second wavelength ⁇ 2, and the absorbance of the mixture X at the third wavelength ⁇ 3.
- Step S2 for deriving a hematocrit value using at least one of the first actual measurement value D1 to the fifth actual measurement value D5, the fifth actual measurement value D5, and the first actual measurement value D1 to the fourth actual measurement value D4 and the regression calculation Correction is performed using the obtained correction coefficient to obtain the absorbance of the dye component at the measurement wavelength, and the absorbance of the dye component at the measurement wavelength and the derived hematocrit value in the blood Step S4 for calculating the component to be measured.
- step S1 the first actual measurement value D1 to the fifth actual measurement value D5 are acquired using the light emitting unit 66 and the light receiving unit 72 of the measurement optical system 64.
- the hematocrit value is derived based on the third actual measurement value D3 or based on the third actual measurement value D3 and the first actual measurement value D1.
- the absorbance of hemoglobin is estimated from the third actual measurement value D3, or from the third actual measurement value D3 and the first actual measurement value D1, and the hematocrit value is derived.
- the third actual measurement value D3 or the third actual measurement value D3 and the first actual measurement value D1 includes the absorption of the pigment component
- the third actual measurement value D3 or the third actual measurement value D3 includes the absorption of the pigment component
- the hematocrit value is derived from the correction value obtained by performing the correction calculation for subtracting the dye component absorption from the first measured value D1.
- the hematocrit value is derived from a calibration curve indicating the relationship between the absorbance of the hemoglobin in the mixture X stored in the memory 62 and the hematocrit value.
- step S3 the fifth actual measurement value D5 is actually corrected using the first actual measurement value D1 to the fourth actual measurement value D4 and the correction coefficient obtained by the regression calculation, and the absorbance of the dye component at the measurement wavelength is estimated. ,get.
- step S4 the glucose concentration is calculated from the absorbance of the dye component at the obtained measurement wavelength and the derived hematocrit value using a calibration curve indicating the relationship with the glucose concentration.
- the coloring reagent 22 is a mixed reagent of glucose dehydrogenase (GDH), a tetrazolium salt (WST-4) and an electron mediator.
- GDH glucose dehydrogenase
- WST-4 tetrazolium salt
- the coloring reagent described here is a tetrazolium salt represented by the following [Chemical Formula 1].
- A. In the formula, X Na.
- FIG. 14 shows the absorbance spectrum of WST-4, which is a dye component contained in the above-described color reagent 22 when glucose water having a glucose concentration of 300 mg / dL is used as a specimen (indicated as “dye component 1” in FIG. 14). ) And the absorbance spectrum of tetrazolium salt A, which is a dye component contained in the coloring reagent described herein (indicated as “dye component 2” in FIG. 14).
- the absorbance spectrum of tetrazolium salt A has a larger and clearer absorption peak than the absorbance spectrum of WST-4. Therefore, if the absorption peak of the color reagent containing tetrazolium salt A is used, it is easier to detect the signal representing the absorbance of the dye component than when using the absorption peak of color reagent 22 containing WST-4, and the component to be measured Measurement error can be reduced. Moreover, since the peak wavelength of the tetrazolium salt A is around 650 nm, 650 nm can be used as the fifth wavelength ⁇ 5 that is the measurement wavelength, as in the above-described example. However, as shown in FIG.
- the peak wavelength region of the tetrazolium salt A is shifted to the longer wavelength side than the peak wavelength region of WST-4. Therefore, when the same wavelength as the second wavelength ⁇ 2 used in the above-described example is used, the measurement error of the component to be measured is likely to occur because it is greatly affected by the light absorption of the tetrazolium salt A.
- the second wavelength ⁇ 2 in the case of using the color reagent containing the tetrazolium salt A is the long wavelength region W1
- the absorbance of the dye component contained in the total absorbance at the second wavelength ⁇ 2 is the total absorbance at the measurement wavelength.
- the wavelength is 10% or less, preferably 6% or less, more preferably 3% or less, and still more preferably substantially 0% of the absorbance of the dye component contained in.
- the measurement wavelength is 650 nm
- the wavelength is preferably 950 nm or less, and more preferably 940 nm or less.
- the first wavelength ⁇ 1 the third wavelength ⁇ 3, the fourth wavelength ⁇ 4, and the fifth wavelength ⁇ 5
- a wavelength range similar to the wavelength range shown in the above example can be used. Then, if the same component measurement method as in the above example is executed using the first wavelength ⁇ 1 to the fifth wavelength ⁇ 5, the optical characteristics due to blood cell components in the blood, reduced hemoglobin and oxidized hemoglobin in erythrocytes, Therefore, it is possible to obtain a highly accurate measurement result.
- the first wavelength ⁇ 1 is 810 nm
- the second wavelength ⁇ 2 is 900 nm
- 545 nm as the third wavelength ⁇ 3 and 560 nm as the fourth wavelength ⁇ 4 regression analysis was performed using the equation [Equation 1] shown in the above example.
- the regression analysis technique is the same as that shown in the above example.
- FIG. 15 shows, in this regression calculation, the influence (measured as “W1” in FIG. 15) of the absorbance (noise) other than the dye component at the measurement wavelength due to the actually measured value in the long wavelength region W1, and the short wavelength. It is a graph which shows the influence degree (it describes with "W2" in FIG. 15) by the actual value of the area
- the absorbance (noise) other than the dye component at the measurement wavelength is estimated using the first measured value D1 to the fourth measured value D4, the first wavelength ⁇ 1 and the second wavelength ⁇ 2 in the long wavelength region W1.
- the influence of the first actual measurement value D1 and the second actual measurement value D2 decreases from 90% to 88% (see “W1” in FIG. 15).
- the third actual measurement value D3 and the fourth actual measurement value D4 at the third wavelength ⁇ 3 and the fourth wavelength ⁇ 4 in the short wavelength region W2 increase from 10% as the hematocrit value increases from 10% to 70%.
- the degree of influence increases to 12% (see “W2” in FIG. 15).
- the absorbance of the dye component at the measurement wavelength can be estimated more accurately.
- the first actual measurement value D1 to the fourth actual measurement value D4 include absorption of the dye component
- correction calculation is performed on the first actual measurement value D1 to the fourth actual measurement value D4 to obtain the absorbance (noise) other than the dye. It is necessary to calculate B ( ⁇ ).
- FIG. 16A uses 810 nm as the first wavelength ⁇ 1, 900 nm as the second wavelength ⁇ 2, 545 nm as the third wavelength ⁇ 3, 560 nm as the fourth wavelength ⁇ 4, and 650 nm as the fifth wavelength ⁇ 5 as the measurement wavelength.
- it is a graph showing an error between the absorbance other than the dye component at the measurement wavelength derived by the component measuring method of the component measuring apparatus 1 and the true value of the absorbance other than the dye component at the same measurement wavelength.
- the absorbance of the dye component contained in the total absorbance at the second wavelength ⁇ 2 corresponds to 1% of the absorbance contained in the total absorbance at the measurement wavelength.
- FIG. 1 uses 810 nm as the first wavelength ⁇ 1, 900 nm as the second wavelength ⁇ 2, 545 nm as the third wavelength ⁇ 3, 560 nm as the fourth wavelength ⁇ 4, and 650 nm as the fifth wavelength ⁇ 5 as the measurement wavelength.
- FIG. 16A uses 810 nm as the
- 16B shows, as a comparative example, the measurement wavelength (650 nm) derived by the same method using only two of 810 nm and 900 nm out of the first wavelength ⁇ 1 to the fourth wavelength ⁇ 4 described above. Is a graph showing an error between the absorbance other than the dye component and the true value of the absorbance other than the dye component at the same measurement wavelength.
- the error shown in FIG. 16A is twice the standard error is 0.0085, whereas the error shown in FIG. 16B is twice the standard error is 0.0140. It can be seen that the error shown in (a) is smaller than the error shown in FIG. That is, regardless of the type of the color reagent, according to the component measurement method executed by the component measurement apparatus 1, the dye at the measurement wavelength estimated from only two wavelengths in the long wavelength region W1 (810 nm and 900 nm in this verification experiment) It is possible to estimate the absorbance with higher accuracy than the absorbance of the component. In this example, when the hematocrit is 40%, the absorbance error 0.002 corresponds to an error of 1 [mg / dL] in blood glucose level.
- the component measuring apparatus 1 using this component measuring method can reduce blood sugar level measurement errors for blood having a wide range of hematocrit values of hematocrit of 10% to 70%.
- the second wavelength ⁇ 2 used in this example is 900 nm, and belongs to a wavelength region on the longer wavelength side than 750 nm, which is the second wavelength ⁇ 2 used in the above-described example. Therefore, the value of the second wavelength ⁇ 2 when using the color reagent containing the tetrazolium salt A is compared with the value of the second wavelength ⁇ 2 when using the color reagent 22 containing WST-4 from the measurement wavelength of 650 nm. Will leave. Therefore, from this viewpoint, the measurement error is likely to occur.
- tetrazolium salt A has a larger absorption peak than WST-4, it is easier to detect a signal representing the absorbance of the dye component. This signal strength can suppress an increase in measurement error due to the second wavelength ⁇ 2 being away from the measurement wavelength. As a result, the measurement error of the component to be measured can be reduced even if the second wavelength ⁇ 2 that is far from the measurement wavelength is used.
- the component measuring apparatus, the component measuring method, and the component measuring program according to the present invention are not limited to the specific description of the above-described embodiment, and various kinds of components can be used without departing from the gist of the invention described in the claims. It can be changed.
- the glucose concentration is measured as the measurement of glucose as a component to be measured, but is not limited to the concentration, and another physical quantity may be measured.
- glucose in the plasma component is exemplified as the component to be measured in blood.
- the present invention is not limited to this.
- cholesterol in blood can be used as the component to be measured. It is. Therefore, the component measuring device is not limited to the blood glucose level measuring device.
- a plurality of types of first to fifth light sources 67a to 67d and 68 have been described as examples of the light emitting unit 66.
- a single light source and a light source disposed in front of the light source are disposed.
- a plurality of types of optical filters (bandpass type) may be combined. Or you may comprise combining a single light source and multiple types of light-receiving part.
- the light receiving unit 72 that receives the transmitted light that passes through the component measuring chip 2 is used.
- the light receiving unit that receives the reflected light reflected from the component measuring chip 2 may be used.
- the present invention relates to a component measuring device, a component measuring method, and a component measuring program, and more particularly, to a component measuring device, a component measuring method, and a component measuring program for measuring a component to be measured in blood.
- Component measuring device 2 Component measuring chip 10: Housing 10a: Main body part 10b: Chip mounting part 11: Display part 12: Removal lever 13: Power button 14: Operation button 21: Base member 22: Coloring reagent (reagent) 23: flow path 24: supply unit 25: cover member 26: eject pin 60: calculation unit 62: memory 63: power supply circuit 64: measurement optical system 66: light emitting units 67a to 67d: first light source to fourth light source 68: first 5 light source 70: light emission control circuit 72: light receiving unit 74: light receiving control circuit 76: measurement instruction unit 77: concentration measuring unit 78: absorbance acquisition unit 84: absorbance correction unit 85: measured value data 86: correction coefficient data 90: calibration curve Data 100: Component measuring device set D1 to D5: First measured value to fifth measured value S: Chip mounting space W1: Long wavelength region W2: Short wavelength region W3: Wavelength range corresponding to full width at half maximum X: Mixture ⁇ 1 to ⁇ 5: 1st wavelength to 5th
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
2:成分測定チップ
10:ハウジング
10a:本体部
10b:チップ装着部
11:表示部
12:取り外しレバー
13:電源ボタン
14:操作ボタン
21:ベース部材
22:発色試薬(試薬)
23:流路
24:供給部
25:カバー部材
26:イジェクトピン
60:演算部
62:メモリ
63:電源回路
64:測定光学系
66:発光部
67a~67d:第1光源~第4光源
68:第5光源
70:発光制御回路
72:受光部
74:受光制御回路
76:測定指示部
77:濃度測定部
78:吸光度取得部
84:吸光度補正部
85:実測値データ
86:補正係数データ
90:検量線データ
100:成分測定装置セット
D1~D5:第1実測値~第5実測値
S:チップ装着空間
W1:長波長域
W2:短波長域
W3:半値全幅域に対応する波長範囲
X:混合物
λ1~λ5:第1波長~第5波長
Claims (15)
- 血液中の被測定成分と試薬との呈色反応により呈色した色素成分を含む混合物の光学的特性に基づいて前記血液中の被測定成分を測定する成分測定装置であって、
散乱光の情報と、赤血球中の還元ヘモグロビンと酸化ヘモグロビンとの比率と、に基づいて、測定波長における前記混合物の吸光度の実測値を補正する成分測定装置。 - 前記実測値を第5実測値とした場合に、
前記色素成分の吸光度スペクトルにおけるピーク波長域の半値全幅域に対応する波長範囲に属する前記測定波長よりも長波長域に属する第1波長及び第2波長それぞれにおける前記混合物の吸光度である第1実測値及び第2実測値、前記半値全幅域に対応する前記波長範囲に属する前記測定波長よりも短波長域に属する第3波長及び第4波長それぞれにおける前記混合物の吸光度である第3実測値及び第4実測値、並びに、前記測定波長における前記混合物の吸光度である前記第5実測値、を取得する吸光度取得部と、
前記第5実測値を、前記第1実測値~第4実測値を用いて補正する吸光度補正部と、を備え、
前記第3波長として、還元ヘモグロビンと酸化ヘモグロビンとの吸収係数の差が、所定値以下となる波長を用いると共に、前記第4波長として、前記吸収係数の差が、前記所定値より大きくなる波長を用いる、請求項1に記載の成分測定装置。 - 前記第3波長として、還元ヘモグロビンの吸収係数に対する酸化ヘモグロビンの吸収係数の比率が、所定の閾値以上となる波長を用いると共に、前記第4波長として、還元ヘモグロビンの吸収係数に対する酸化ヘモグロビンの吸収係数の比率が、前記所定の閾値未満となる波長を用いる、請求項2に記載の成分測定装置。
- 前記第3波長として、還元ヘモグロビンの吸収係数と酸化ヘモグロビンの吸収係数とが等しい波長を用いる、請求項2又は3に記載の成分測定装置。
- 前記第3波長は、520nm~550nmの範囲又は565nm~585nmの範囲に属する、請求項2乃至4のいずれか1つに記載の成分測定装置。
- 前記第4波長は、550nmより大きく、かつ、565nm未満の範囲に属する、又は、585nmより大きく、かつ、600nm未満の範囲に属する、請求項5に記載の成分測定装置。
- 前記所定値を第1の所定値とした場合に、
前記第1波長として、還元ヘモグロビンと酸化ヘモグロビンとの吸収係数の差が、第2の所定値以下となる波長を用いると共に、前記第2波長として、前記第2の所定値より大きくなる波長を用いる、請求項2乃至6のいずれか1つに記載の成分測定装置。 - 前記所定の閾値を第1閾値とした場合に、
前記第1波長として、還元ヘモグロビンの吸収係数に対する酸化ヘモグロビンの吸収係数の比率が、前記第1閾値以上、かつ、第2閾値以下となる波長を用いると共に、前記第2波長として、還元ヘモグロビンの吸収係数に対する酸化ヘモグロビンの吸収係数の比率が、前記第1閾値未満となる波長、又は、前記第2閾値より大きくなる波長を用いる、請求項3に記載の成分測定装置。 - 前記第1波長として、還元ヘモグロビンの吸収係数と酸化ヘモグロビンの吸収係数とが等しい波長を用いる、請求項7又は8に記載の成分測定装置。
- 前記第1波長は、790nm~810nmの範囲に属する、請求項7乃至9のいずれか1つに記載の成分測定装置。
- 前記第2波長は、前記色素成分の吸光度が、前記測定波長における前記色素成分の吸光度の10%以下となる波長に属する、請求項7乃至10のいずれか1つに記載の成分測定装置。
- 前記第2波長は、前記色素成分の吸光度が、前記測定波長における前記色素成分の吸光度の0%となる波長である、請求項11に記載の成分測定装置。
- 前記測定波長は、600nm以上、かつ、700nm以下の範囲に属する、請求項1乃至12のいずれか1つに記載の成分測定装置。
- 血液中の被測定成分と試薬との呈色反応により呈色した色素成分を含む混合物の光学的特性に基づいて前記血液中の被測定成分を測定する成分測定方法であって、
散乱光の情報と、赤血球中の還元ヘモグロビンと酸化ヘモグロビンとの比率と、に基づいて、測定波長における前記混合物の吸光度の実測値を補正する成分測定方法。 - 血液中の被測定成分と試薬との呈色反応により呈色した色素成分を含む混合物の光学的特性に基づいて前記血液中の被測定成分を測定するための成分測定プログラムであって、
散乱光の情報と、赤血球中の還元ヘモグロビンと酸化ヘモグロビンとの比率と、に基づいて、測定波長における前記混合物の吸光度の実測値を補正することを、成分測定装置に実行させる成分測定プログラム。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018503993A JP6757400B2 (ja) | 2016-03-08 | 2016-11-17 | 成分測定装置、成分測定方法及び成分測定プログラム |
EP16893594.8A EP3428623B1 (en) | 2016-03-08 | 2016-11-17 | Component measurement device, component measurement method, and component measurement program |
CN201680075916.0A CN108463715A (zh) | 2016-03-08 | 2016-11-17 | 成分测定装置、成分测定方法以及成分测定程序 |
KR1020187025689A KR20180118661A (ko) | 2016-03-08 | 2016-11-17 | 성분 측정 장치, 성분 측정 방법 및 성분 측정 프로그램 |
US16/115,682 US11320382B2 (en) | 2016-03-08 | 2018-08-29 | Component measurement device, component measurement method, and component measurement program |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-044694 | 2016-03-08 | ||
JP2016044694 | 2016-03-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/115,682 Continuation US11320382B2 (en) | 2016-03-08 | 2018-08-29 | Component measurement device, component measurement method, and component measurement program |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017154270A1 true WO2017154270A1 (ja) | 2017-09-14 |
Family
ID=59789125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/084049 WO2017154270A1 (ja) | 2016-03-08 | 2016-11-17 | 成分測定装置、成分測定方法及び成分測定プログラム |
Country Status (6)
Country | Link |
---|---|
US (1) | US11320382B2 (ja) |
EP (1) | EP3428623B1 (ja) |
JP (1) | JP6757400B2 (ja) |
KR (1) | KR20180118661A (ja) |
CN (1) | CN108463715A (ja) |
WO (1) | WO2017154270A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018061772A1 (ja) * | 2016-09-29 | 2018-04-05 | テルモ株式会社 | 成分測定装置、成分測定方法及び成分測定プログラム |
WO2018173609A1 (ja) * | 2017-03-23 | 2018-09-27 | テルモ株式会社 | 成分測定装置及び成分測定装置セット |
JP2020504292A (ja) * | 2016-11-18 | 2020-02-06 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 液体アッセイの複数順次波長測定 |
WO2020137532A1 (ja) * | 2018-12-28 | 2020-07-02 | テルモ株式会社 | テストストリップ及び成分測定システム |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108872227B (zh) * | 2018-08-30 | 2021-07-06 | 河南省科学院高新技术研究中心 | 一种快速鉴别温县铁棍山药的试剂及其鉴别方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002306458A (ja) * | 2001-04-19 | 2002-10-22 | Nippon Koden Corp | 血中吸光物質濃度測定装置および血中吸光物質濃度を演算するための補正関数決定方法 |
JP2014233344A (ja) * | 2013-05-31 | 2014-12-15 | Hoya株式会社 | 光学フィルタ素子、波長可変光バンドパスフィルタモジュール、波長可変光源装置及び分光内視鏡装置 |
WO2015137074A1 (ja) * | 2014-03-14 | 2015-09-17 | テルモ株式会社 | 成分測定装置、方法及びプログラム |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE466157B (sv) | 1989-04-25 | 1992-01-07 | Migrata Uk Ltd | Saett att bestaemma glukoshalten hos helblod samt engaangskuvett foer detta |
JP2000262298A (ja) * | 1999-03-15 | 2000-09-26 | Fuji Photo Film Co Ltd | 全血中のグルコース濃度もしくはコレステロール濃度の定量方法 |
AU2003234785A1 (en) | 2002-05-08 | 2003-11-11 | Arkray, Inc. | Ingredient concentration measurement method and device |
JP3566277B1 (ja) * | 2003-06-23 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
ATE508357T1 (de) * | 2004-12-13 | 2011-05-15 | Bayer Healthcare Llc | Transmissionspektroskopiesystem zur verwendung bei der bestimmung von analyten in körperflüssigkeit |
US20080248581A1 (en) * | 2007-04-06 | 2008-10-09 | Bayer Healthcare Llc | Method for performing correction of blood glucose assay bias using blood hemoglobin concentration |
-
2016
- 2016-11-17 JP JP2018503993A patent/JP6757400B2/ja active Active
- 2016-11-17 KR KR1020187025689A patent/KR20180118661A/ko not_active Application Discontinuation
- 2016-11-17 EP EP16893594.8A patent/EP3428623B1/en active Active
- 2016-11-17 CN CN201680075916.0A patent/CN108463715A/zh active Pending
- 2016-11-17 WO PCT/JP2016/084049 patent/WO2017154270A1/ja active Application Filing
-
2018
- 2018-08-29 US US16/115,682 patent/US11320382B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002306458A (ja) * | 2001-04-19 | 2002-10-22 | Nippon Koden Corp | 血中吸光物質濃度測定装置および血中吸光物質濃度を演算するための補正関数決定方法 |
JP2014233344A (ja) * | 2013-05-31 | 2014-12-15 | Hoya株式会社 | 光学フィルタ素子、波長可変光バンドパスフィルタモジュール、波長可変光源装置及び分光内視鏡装置 |
WO2015137074A1 (ja) * | 2014-03-14 | 2015-09-17 | テルモ株式会社 | 成分測定装置、方法及びプログラム |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018061772A1 (ja) * | 2016-09-29 | 2018-04-05 | テルモ株式会社 | 成分測定装置、成分測定方法及び成分測定プログラム |
JPWO2018061772A1 (ja) * | 2016-09-29 | 2019-07-11 | テルモ株式会社 | 成分測定装置、成分測定方法及び成分測定プログラム |
JP2020504292A (ja) * | 2016-11-18 | 2020-02-06 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | 液体アッセイの複数順次波長測定 |
WO2018173609A1 (ja) * | 2017-03-23 | 2018-09-27 | テルモ株式会社 | 成分測定装置及び成分測定装置セット |
EP3605069A4 (en) * | 2017-03-23 | 2021-01-06 | Terumo Kabushiki Kaisha | DEVICE FOR MEASURING A COMPONENT AND SET OF MEASURING DEVICES FOR A COMPONENT |
US11703456B2 (en) | 2017-03-23 | 2023-07-18 | Terumo Kabushiki Kaisha | Component measurement device and component measurement device set |
WO2020137532A1 (ja) * | 2018-12-28 | 2020-07-02 | テルモ株式会社 | テストストリップ及び成分測定システム |
CN112997067A (zh) * | 2018-12-28 | 2021-06-18 | 泰尔茂株式会社 | 测试条以及成分测定系统 |
JPWO2020137532A1 (ja) * | 2018-12-28 | 2021-11-11 | テルモ株式会社 | テストストリップ及び成分測定システム |
JP7442461B2 (ja) | 2018-12-28 | 2024-03-04 | テルモ株式会社 | 成分測定システム |
Also Published As
Publication number | Publication date |
---|---|
EP3428623A4 (en) | 2019-10-16 |
US11320382B2 (en) | 2022-05-03 |
EP3428623B1 (en) | 2021-06-16 |
KR20180118661A (ko) | 2018-10-31 |
JPWO2017154270A1 (ja) | 2019-01-10 |
CN108463715A (zh) | 2018-08-28 |
EP3428623A1 (en) | 2019-01-16 |
US20190011371A1 (en) | 2019-01-10 |
JP6757400B2 (ja) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018173609A1 (ja) | 成分測定装置及び成分測定装置セット | |
US11320382B2 (en) | Component measurement device, component measurement method, and component measurement program | |
JP6426702B2 (ja) | 成分測定装置、方法及びプログラム | |
US9651564B2 (en) | Device and method for measuring hemoglobin | |
EP3861318B1 (en) | Disposable hemolysis sensor | |
WO2009119213A1 (ja) | ヘマトクリット値または血液成分濃度の測定方法および測定装置 | |
EP1790974B1 (en) | Colorimetric blood glucose meter | |
JP7028778B2 (ja) | HbA1cの測定法 | |
WO2018061772A1 (ja) | 成分測定装置、成分測定方法及び成分測定プログラム | |
JP5290752B2 (ja) | コントロール液の自動判別方法 | |
Kudavelly et al. | A simple and accurate method for estimating bilirubin from blood | |
US10126232B2 (en) | Sample test method, microfluidic device, and test device | |
WO2016147527A1 (ja) | 成分測定装置セット及び体液測定チップ | |
EP3180614B1 (en) | Sample test method and test device | |
US20220371016A1 (en) | Component measurement apparatus, component measurement apparatus set, and information processing method | |
US20230349823A1 (en) | Component measurement device, component measurement device set, and information processing method | |
US20220390380A1 (en) | Component measurement apparatus, component measurement apparatus set, and information processing method | |
WO2021166561A1 (ja) | 成分測定装置、成分測定装置セット及び情報処理方法 | |
WO2021166606A1 (ja) | 成分測定装置、成分測定装置セット及び情報処理方法 | |
CN113533224A (zh) | 一种抗干扰检测方法及样本分析仪 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018503993 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187025689 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016893594 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016893594 Country of ref document: EP Effective date: 20181008 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16893594 Country of ref document: EP Kind code of ref document: A1 |